Harada, Guilherme http://orcid.org/0000-0003-4012-3251
Yang, Soo-Ryum
Cocco, Emiliano
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Article History
Accepted: 17 January 2023
First Online: 20 February 2023
Competing interests
: G.H. has acted as an adviser to AstraZeneca, Bayer, Lilly, Merck and MSD. S.-R.Y. has received honoraria from PRIME Education LLC. E.C. has acted as a consultant of ENTOS Inc., and has received research funding from ERASCA and InnoCare pharma. A.D. has acted as an adviser to Abbvie, AiCME, Amgen, Applied Pharmaceutical Science, ArcherDX, AstraZeneca, AXIS, Beigene, BergenBio, Blueprint Medicines, Chugai Pharmaceutical, EMD Serono, Entos, EPG Health, Equity Treeline Bio, Exelixis, Harborside Nexus, Helsinn, Hengrui Therapeutics, i3 Health, Ignyta/Genentech/Roche, Janssen, Liberum, Loxo/Bayer/Lilly, mBrace, Medendi, Merus, Monopteros, MORE Health, MonteRosa, 14ner/Elevation Oncology, Novartis, Nuvalent, Ology, Pfizer, Prelude Inc., Remedica Ltd, Repare RX, RV More, Takeda/Ariad/Millenium, TouchIME, TP Therapeutics, Treeline Bio, Tyra Biosciences and Verastem; receives royalties from Wolters Kluwer; receives CME honoraria from Axis, Answers in CME, Clinical Care Options, EPG Health, Imedex, JNCC/Harborside, Liberum, Med Learning, Medscape, MJH Life Sciences, OncLive, Paradigm Medical Communications, Peerview Institute, PeerVoice, Physicians Education Resources, Remedica Ltd, Research to Practice, Targeted Oncology & WebMD; receives institutional research funding from Exelixis, GlaxoSmithKlein, Pfizer, PharmaMar, Taiho and Teva; receives other support from Boehringer Ingelheim; Merck, Merus & Puma; and is listed on a copyright application relating to the use of selpercatinib–osimertinib.